

HANDBOOK OF INFLAMMATION 3

L.E. Glynn, John C. Houck and Gerald Weissmann Editors

Tissue Repair and Regeneration

L.E. GLYNN Editor


Elsevier/North-Holland

Tissue repair and regeneration

Editor

L.E. GLYNN

*Canadian Red Cross Memorial Hospital, Taplow,
Maidenhead, Berks.,
England*



1981

ELSEVIER/NORTH-HOLLAND BIOMEDICAL PRESS
AMSTERDAM · NEW YORK · OXFORD

© Elsevier/North-Holland Biomedical Press

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

Published by:

Elsevier/North-Holland Biomedical Press
1, Molenwerf, P.O. Box 211
1014 AG Amsterdam, The Netherlands

Sole distributors for the U.S.A. and Canada:

Elsevier/North-Holland Inc.
52 Vanderbilt Avenue
New York, N.Y. 10017

ISBN Vol. 3: 0-444-80278-9

ISBN SERIES: 0-444-80118-9

Library of Congress Cataloging in Publication Data

Main entry under title:

Tissue repair and regeneration.

(Handbook of inflammation; v. 3)

Bibliography: p.

Includes index.

1. Regeneration (Biology) 2. Wound healing.

3. Tissues. I. Glynn, L. E. (Leonard Eleazar),
1910— II. Series. [DNLM: 1. Regeneration.
2. Wound healing. W1 HA51PS v. 3/QZ 150 T616]
RB131.H27 vol. 3 [QP90.2] 616'.0473s 81-1653
ISBN 0-444-80278-9 [611'.018] AACR2

Printed in the Netherlands

Preface

The editors propose to publish, over the course of the next few years, a series of at least five volumes entitled 'The Handbook of Inflammation', each volume focussing on a major element of the inflammatory process. Insofar as possible the editors have endeavored to select authors who were both knowledgeable and willing to review in detail the voluminous literature of their particular view of the field of inflammation in an interdisciplinary fashion. Each of the various editors are solely responsible for the selection of authors and subject of each volume, while all of the editors collectively are responsible for the volume topic.

The purpose of the series is to provide detailed and definitive reports of many of the multiplex components which go into the inflammatory process and to do this on an interdigitated and integrated basis. Because of the multidisciplinary aspects of inflammation, this is both necessary and difficult. In this field investigators must be capable of both 'looking down the tube' as well as 'pouring things into it'. To some workers the expression 'broken cell' means biological and membrane disaster, whereas to others it means that the ultracentrifuge is broken. Over the past decade, however, biologists have learned biochemistry to some degree and biochemists have had to learn some biology. Because of a shared vocabulary which has been developing as a consequence of this understanding of another discipline, a greater dialogue is now possible about inflammation than ever before. It is the conclusion of the editors that the compilation of interdisciplinary reviews side-by-side in the same volume will contribute to the further development of this colloquy.

L.E.G.
J.C.H.
G.W.

Volume 1—Chemical messengers of the inflammatory process
Volume 2—The cell biology of inflammation
Volume 3—Tissue repair and regeneration
Volume 4—Immunology of inflammation
Volume 5—The molecular basis for anti-inflammatory therapy

Introduction to volume three

The first two volumes of this series have dealt with the various aspects of the inflammatory response that, depending upon the intensity and persistence of the initiating agent, result in accumulations of cells and fluids associated with various degrees of local tissue necrosis. The present volume takes up the story when the primary cause of the tissue injury has been contained or overcome, and lost tissue must be replaced either by specific cells capable of functioning in the same way as those that are lost or by connective tissue where such replacement is impossible.

Although it is convenient for descriptive purposes to separate those aspects of the inflammatory process that lead to the neutralisation of the causative stimulus from those which lead to the replacement of the lost tissue, it is essential to appreciate that both components of the inflammatory reaction proceed simultaneously but with degrees of intensity which differ markedly according to the stage of the process. In chronic reactions, that is those in which the causative agent is only overcome with difficulty or not at all, both phases of the reaction contribute conspicuously and simultaneously to the pathological picture.

The processes of healing differ strikingly in the various tissues and organs, depending mainly upon the capacity or otherwise of the affected organ to replace lost cells by those of the same kind. Where this capacity is absent the healing process is brought about by the new formation of connective tissue in which collagen is the predominant component and the end result a scar. In those organs, however, in which the lost cells can be entirely replaced, the newly formed tissue is indistinguishable from its surroundings and no scar tissue is formed. In most organs of this kind, however, especially if the original supporting connective tissue framework has been destroyed with the specific parenchymal cells, the final healing presents a composite picture in which the original architecture is lost or obscured.

Factors responsible for and modifying the healing process will obviously differ depending upon whether it is predominantly of the kind leading to scar formation or of the regeneration variety. In the formation of scar tissue the fibroblast is the key cell and collagen its principal product. The non-collagen components of connective tissue are also secreted by these cells and the factors responsible for the stimulation of fibroblasts to proliferate and to secrete are therefore of major significance in the healing process. These cells are highly dependent upon various nutritional factors, both specific and nonspecific, and in recent years their hormonal susceptibilities have become increasingly apparent.

Since the healing process is considerably modified by the organ or tissue in which it is occurring it is necessary to consider the manner in which this modification arises and how in its turn the end result modifies the structure and function of the healed organ. It has therefore been necessary to consider each organ and tissue independently.

Before the processes of repair or regeneration can make reasonable progress it is important that the site of their operations be adequately cleared of necrotic tissue and exudate. This is largely a function of extracellular enzyme activity supplemented by intra cellular digestion, in both of which activities the monocyte-macrophage system plays the dominant role.

Although the healing process is usually preceded by an obviously noxious or traumatic stimulus, this is not invariable and several important forms of scar formation are not preceded by any obvious cause, e.g. scleroderma, or Dupuytren's contracture. Whether the site of the primary stimulus is the fibroblast or the parenchyma in which it is situated is still a moot point. Such examples of scar formation are also considered in this volume since their understanding must contribute significantly to the clarification of the formation of scar tissue in general.

Finally, the healing process, as already stated, frequently involves regeneration. Adequate consideration of this merges imperceptibly into that of atrophy and hypertrophy both of which are active processes involving both anabolic as well as catabolic processes.

L.E. Glynn

List of contributors

S.Y. Ali	343
<i>Institute of Orthopaedics (University of London), at the Royal National Orthopaedic Hospital, 234 Great Portland Street, London and Brockley Hill, Stanmore, England</i>	
Allen J. Bailey	51
<i>Department of Animal Husbandry, University of Bristol and Agricultural Research Council, Meat Research Institute, Langford, Bristol, England</i>	
Geoffrey H. Bourne	211
<i>Department of Nutrition, St. George's University School of Medicine, Grenada, West Indies</i>	
Paul D. Byers	343
<i>Institute of Orthopaedics (University of London), at the Royal National Orthopaedic Hospital, 234 Great Portland Street, London and Brockley Hill, Stanmore, England</i>	
C. William Castor	177
<i>Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI 48109</i>	
D.J. Davies	515
<i>Department of Anatomical Pathology, St. Vincent's Hospital, Fitzroy, Victoria, Australia</i>	

Victor C. Duance	51
<i>Department of Animal Husbandry, University of Bristol and Agricultural Research Council, Meat Research Institute, Langford, Bristol, England</i>	
L.W. Duchen	383
<i>Department of Neuropathology, Institute of Neurology and the National Hospital for Nervous Diseases, Queen Square, London, England</i>	
G. Gabbiani	1
<i>Department of Pathology, University of Geneva, CH-1211 Geneva 4, Switzerland</i>	
L.E. Glynn	285
<i>Canadian Red Cross Memorial Hospital, Taplow, Maidenhead, Berks., England</i>	
James Craig Gray	343
<i>Institute of Orthopaedics (University of London), at the Royal National Orthopaedic Hospital, 234 Great Portland Street, London and Brockley Hill, Stanmore, England</i>	
A.G. Heppleston	393
<i>Institute of Occupational Medicine, Roxburgh Place, Edinburgh, EH8 9SU, Scotland</i>	
R. Marks	309
<i>Department of Medicine, Welsh National School of Medicine, Heath Park, Cardiff, Wales</i>	
Cahir A. McDevit	111
<i>Department of Pathology, Basic Health Science, State University of New York at Stony Brook, Stony Brook, NY 11794</i>	
E.F. McKeown	457
<i>Department of Pathology, The Queen's University of Belfast, Northern Ireland</i>	
A.G.S.A. Mostafa	343
<i>Institute of Orthopaedics (University of London), at the Royal National Orthopaedic Hospital, 234 Great Portland Street, London and Brockley Hill, Stanmore, England</i>	
H. Konrad Muller	145
<i>Department of Pathology and Immunology, Monash University Medical School, Alfred Hospital, Melbourne 3181, Australia</i>	

- H. Roels 243
*Department of Pathology and Morbid Anatomy, Akademisch Ziekenhuis,
State University of Ghent, Ghent, Belgium*
- E. Rungger- Brändle 1
*Department of Pathology, University of Geneva, CH-1211 Geneva 4,
Switzerland*
- G.B. Ryan 515
*Department of Anatomy, University of Melbourne, Parkville, Victoria,
Australia*
- F. Scaravilli 383
*Department of Neuropathology, Institute of Neurology and the National
Hospital for Nervous Diseases, Queen Square, London, England*

Contents

<i>Series preface</i>	v
<i>Introduction to volume three</i>	vii
<i>List of contributors</i>	ix
 1. <i>The fibroblast</i>	 1
<i>G. Gabbiani and E. Rungger-Brändle</i>	
1.1. Introduction	1
1.2. The fibroblast in vivo	1
1.3. The cultivated fibroblast	
1.3.1. Morphologic features	4
1.3.2. Locomotion and adhesion to the substrate	10
1.3.3. Growth	12
1.3.4. Synthesis of extracellular components	17
1.3.4.1. Collagen	17
1.3.4.2. Proteoglycans	18
1.3.5. Aging	20
1.4. The fibroblast of granulation tissue (myofibroblast)	22
1.4.1. Morphology	22
1.4.2. Pharmacology	24
1.4.3. Chemistry	25
1.4.4. Immunology	25
1.4.5. Collagen synthesis	26
1.4.6. Conclusion	27
1.5. Overview	29
 2. <i>Biosynthesis and degradation of collagen</i>	 51
<i>Victor C. Duance and Allen J. Bailey</i>	
2.1. Introduction	51
2.2. Collagen structure	51
2.2.1. Molecular structure	52
2.2.1.1. Primary sequence	52

	2.2.1.2.	Glycosylation	53
	2.2.1.3.	Molecular conformation	53
	2.2.2.	Fibre structure	54
	2.2.3.	Intermolecular cross-links	55
	2.2.3.1.	Cross-link structure	55
	2.2.3.2.	Cross-link location	56
	2.2.3.3.	Changes in cross-linking with age	57
	2.2.4.	Collagen polymorphism	58
	2.2.4.1.	Type II collagen	58
	2.2.4.2.	Type III collagen	58
	2.2.4.3.	Type IV collagen	60
	2.2.4.4.	Type V or AB collagen	62
	2.2.4.5.	Other collagenous molecules	62
2.3.		The biosynthesis of collagen	63
	2.3.1.	Procollagen structure	63
	2.3.2.	Procollagen synthesis	64
	2.3.3.	Intracellular post-translational modifications	66
	2.3.3.1.	4-Prolyl hydroxylase	66
	2.3.3.2.	Lysyl hydroxylase	67
	2.3.3.3.	Glycosylation of hydroxylysine	67
	2.3.3.4.	Triple-helix formation	68
	2.3.4.	Extracellular post-translational modifications	68
	2.3.4.1.	Procollagen secretion	68
	2.3.4.2.	Conversion of procollagen to collagen	69
	2.3.4.3.	Fibril formation	70
	2.3.4.4.	Biosynthesis of collagen cross-links	70
2.4.		Collagen degradation	71
	2.4.1.	Collagenases	71
	2.4.2.	Neutral proteases	73
	2.4.3.	Lysosomal cathepsins	73
	2.4.4.	Physiological routes for the resorption of collagen	74
2.5.		Immunology of collagen	75
	2.5.1.	Antigenic determinants of collagen	75
	2.5.1.1.	Helical determinants	75
	2.5.1.2.	Nonhelical determinants	76
	2.5.1.3.	Helical conformation independent determinants	77
	2.5.1.4.	Procollagen determinants	77
	2.5.2.	Cell mediated immunity	78
	2.5.3.	The use of anticollagen antibodies in the study of collagen	78
2.6.		Involvement of collagen in inflammation	79
	2.6.1.	Collagen-platelet interaction	79
	2.6.2.	Experimental granulation tissue	81
	2.6.3.	Scars and keloids	82
	2.6.4.	Fibrosis	83
	2.6.5.	Enzymic degradation of collagen in inflammatory conditions	85
	2.6.5.1.	Wound healing	86
2.7.		Regulation and pharmacological control of biosynthesis and degradation	86
	2.7.1.	Regulation of collagen biosynthesis	86
	2.7.2.	Regulation of collagen catabolism	88
	2.7.2.1.	Hormonal control	88
	2.7.2.2.	Control by enzyme-inhibitor complexes or latent enzymes	88
2.8.		Concluding remarks	89
3.		<i>The proteoglycans of cartilage and the intervertebral disc in ageing and osteoarthritis</i>	111
		<i>Cahir A. McDevitt</i>	
3.1.		Definition of proteoglycans	111
	3.1.1.	Introduction	111
	3.1.2.	Proteoglycans: general definition	112

3.1.3.	Nomenclature of proteoglycans and glycosaminoglycans	112
3.2.	Glycosaminoglycans	113
3.2.1.	Structure of glycosaminoglycans	113
3.2.2.	Size of glycosaminoglycans	115
3.2.3.	Conformation of the glycosaminoglycans	116
3.2.4.	Linkage of glycosaminoglycans to protein	116
3.2.5.	The oligosaccharides of proteoglycans	117
3.3.	Proteoglycans	117
3.3.1.	Structure of hyaline cartilage proteoglycans	117
3.3.2.	Extraction of proteoglycans	120
3.3.3.	Equilibrium density gradient isolation and demonstration of reversible aggregation in proteoglycans	122
3.3.4.	The role of hyaluronic acid in proteoglycan aggregation	123
3.3.5.	Link proteins and proteoglycan aggregation	124
3.3.6.	Nomenclature for identification of isolated proteoglycans (A1, D1 and A1-D1 fractions)	125
3.3.7.	Polydispersity of proteoglycans	125
3.3.8.	Heterogeneity of proteoglycans	127
3.3.9.	Electron microscopic evaluation of proteoglycans	128
3.3.10.	Intervertebral disc proteoglycans	129
3.4.	Ageing and osteoarthritis	131
3.4.1.	Changes with age in articular cartilage proteoglycans	131
3.4.2.	Changes with age in intervertebral disc proteoglycans	132
3.4.3.	Osteoarthritis	132

4. *Mechanisms of clearing injured tissue* 145

H. Konrad Muller

4.1.	Introduction	145
4.2.	Clearance mechanisms in inflammation	145
4.2.1.	Phagocytosis	145
4.2.1.1.	Chemotaxis	145
4.2.1.2.	Recognition and attachment	147
4.2.1.3.	Ingestion and phagosome formation	147
4.2.1.4.	Degranulation	148
4.2.1.5.	The respiratory burst	148
4.2.1.6.	Microbial killing mechanisms	149
4.2.2.	Lysosomal enzymes	151
4.2.2.1.	Enzyme digestion	151
4.2.2.2.	Endogenous protease inhibitors	153
4.2.3.	Fibrinolysis	155
4.2.4.	Lymphatics drainage	156
4.2.5.	Outcome of tissue injury and inflammatory reaction	157
4.3.	Causes of inadequate clearance	158
4.3.1.	Nature of agent	158
4.3.1.1.	Microbial agents	158
4.3.1.2.	Insoluble particles	159
4.3.2.	Defects of phagocytic function	160
4.3.2.1.	Disorders of mobility and chemotaxis	160
4.3.2.2.	Disorders of attachment, ingestion and degranulation	162
4.3.2.3.	Disorders of microbial killing mechanisms	163
4.3.3.	Deficiency of endogenous protease inhibitors	164
4.3.4.	Persistence of fibrin	164
4.3.5.	Failure of lymphatic drainage	164
4.4.	Consequences of inadequate clearance	165
4.4.1.	Suppuration	165
4.4.2.	Fibrosis	165
4.4.3.	Chronic inflammation and granulomas	165
4.4.4.	Amyloidosis	166
4.4.5.	Autoimmunity	167
4.5.	Conclusion	167

5.	<i>Autacoid regulation of wound healing</i>	177
	<i>C. William Castor</i>	
5.1.	Introduction	177
5.2.	The evolution of wound healing	179
5.3.	Role of inflammatory cells from the blood	181
5.3.1.	The polymorphonuclear leucocyte	181
5.3.2.	The macrophage	182
5.3.3.	The platelets	183
5.4.	Autacoid regulation of the early vascular phase of wound healing	184
5.5.	Regulation of growth and DNA synthesis	186
5.5.1.	Platelet factors	188
5.5.2.	Polymorphonuclear leucocyte growth factor	189
5.5.3.	Multiplication stimulating activity (MSA)	189
5.5.4.	Somatomedins	190
5.5.5.	NSILA	191
5.5.6.	Angiogenic factors	191
5.5.7.	Nerve growth factor	192
5.5.8.	Epidermal growth factor	192
5.5.9.	Fibroblast growth factor (FGF)	192
5.5.10.	Other growth factors	193
5.6.	Factors regulating glycosaminoglycan (GAG) formation	193
5.6.1.	Regulation by protein factors	194
5.6.1.1.	Connective tissue activating peptides-I, -II, and -III and CTAP-PMN	194
5.6.1.2.	NSILA-S and somatomedins A and C	195
5.6.2.	Hormones and vitamins	196
5.6.3.	Prostaglandins and cyclic nucleotides	197
5.7.	Regulation of collagen metabolism	198
5.7.1.	Agents stimulating collagen formation	199
5.7.2.	Protein factors promoting collagen accumulation	199
5.7.3.	Agents depressing collagen synthesis	200
5.7.4.	Factors modifying collagenase formation and release	201
5.8.	Studies of transport mechanisms	201
5.9.	General considerations related to wound healing	202
6.	<i>Nutrition and wound healing</i>	211
	<i>Geoffrey H. Bourne</i>	
6.1.	Introduction	211
6.2.	Collagen production	213
6.3.	Nutritional elements responsible for the healing of wounds	215
6.4.	Vitamin C	215
6.5.	The B vitamins	224
6.6.	Vitamin A	225
6.7.	Vitamin K	228
6.8.	Vitamin D	228
6.9.	Vitamin E	228
6.10.	Protein	229
6.11.	Zinc	231
6.12.	Other metals	234
6.13.	Summary	234
7.	<i>Hyperplasia versus atrophy – Regeneration versus repair</i>	243
	<i>H. Roels</i>	
7.1.	Introduction	243
7.1.1.	The cell division	243
7.1.2.	The regulation of cell division	244
7.1.2.1.	The chalones	246

	7.1.2.2.	Hormone receptors	247
	7.1.2.3.	Other growth stimulating factors	249
	7.1.3.	The growth capacity of tissues	251
7.2.		Hyperplasia versus atrophy	252
	7.2.1.	Definitions	252
	7.2.2.	Examples	253
	7.2.2.1.	Hypertrophy	253
	7.2.2.2.	Hyperplasia	254
	7.2.2.3.	Atrophy	260
7.3.		Regeneration versus repair	263
	7.3.1.	Regeneration	263
	7.3.1.1.	Regeneration of the liver	263
	7.3.1.2.	Regeneration of surface epithelium	265
	7.3.1.3.	Regeneration of striated muscle	266
	7.3.2.	Repair	266
	7.3.2.1.	The basic phenomenon	266
	7.3.2.2.	The choice between regeneration and repair	268
7.4.		Conclusion	272
8.		<i>The pathology of scar tissue formation</i>	285
		<i>L.E. Glynn</i>	
	8.1.	Introduction	285
	8.2.	Hypertrophic scars and keloids	294
	8.3.	Calcification of scar tissue	295
	8.4.	Mucinous and hyaline degeneration in scar tissue	298
	8.5.	Drug-induced fibrosis	300
	8.6.	Idiopathic fibrosis of the skin and other tissues	302
9.		<i>The healing and nonhealing of wounds and ulcers of the skin</i>	309
		<i>R. Marks</i>	
	9.1.	Introduction	309
	9.2.	The healing of wounds of the skin	310
	9.2.1.	Overview	310
	9.2.2.	Epidermal wound healing	310
	9.2.2.1.	Active epidermal cell movement (AECM)	311
	9.2.2.2.	Mitotic activity	315
	9.2.2.3.	Maturation of epidermis	317
	9.2.2.4.	Histochemical and biochemical changes	318
	9.2.2.5.	Hair follicles	319
	9.2.2.6.	Melanocytes	319
	9.2.2.7.	Models for study of epidermal repair	319
	9.2.3.	Blood elements	320
	9.2.4.	Blood vessels	322
	9.2.5.	Fibrous repair	324
	9.3.	Wound contraction	328
	9.4.	The causes of ulceration	329
	9.5.	Complications of ulceration	334
	9.5.1.	Infection and infestation	334
	9.5.2.	Neoplasia	335
	9.6.	Miscellaneous complications of ulceration	335
10.		<i>The healing of bone and articular cartilage</i>	343
		<i>Paul D. Byers, James Craig Gray, A.G.S.A. Mostafa and S.Y. Ali</i>	
	10.1.	Introduction	343
	10.2.	Fracture healing	343
	10.2.1.	The origin of cells in fracture callus	346
	10.2.2.	Osteogenesis in bone grafts	347

	10.2.2.1.	Introduction	347
	10.2.2.2.	Does the new bone come from graft cells or host cells?	348
	10.2.2.3.	Which graft cells give rise to bone formation?	350
	10.2.2.4.	What are the practical implications for surgery?	351
	10.2.3.	Enzymes in fracture healing	351
	10.2.3.1.	Introduction	351
	10.2.3.2.	Alkaline phosphatase	353
	10.2.3.3.	Acid phosphatase	354
	10.2.3.4.	Leucine aminopeptidase	354
	10.2.3.5.	Nonspecific esterases	355
	10.2.3.6.	Beta glucuronidase	355
	10.2.3.7.	Glucose-6-phosphate dehydrogenase	355
	10.2.3.8.	Phosphorylase	355
	10.2.4.	Chemical composition of callus	356
	10.2.5.	Hormones	356
	10.2.6.	Vitamins	358
	10.2.7.	Chemicals and drugs	359
	10.2.8.	Genetic and metabolic disorders of human disease	359
	10.2.9.	Physical factors	359
	10.2.9.1.	Oxygen tension	359
	10.2.9.2.	Physical exercise	360
	10.2.9.3.	Local heat	361
	10.2.9.4.	Venous stasis	361
	10.2.9.5.	Electric and electromagnetic forces	361
10.3.		Articular cartilage repair	363
	10.3.1.	Introduction	363
	10.3.2.	Degeneration and repair	364
	10.3.3.	Arthroplasty	365
	10.3.4.	Osteoarticular and cartilage grafts	366
	10.3.5.	Osteotomy	368
11.		<i>Regeneration in the central nervous system</i>	383
		<i>F. Scaravilli and L.W. Duchen</i>	
	11.1.	Introduction	383
	11.2.	Experimental studies of spinal cord injury	384
	11.3.	Regeneration of spinal sensory root fibres	385
	11.4.	Axonal sprouting	385
	11.5.	Hypotheses for the failure of CNS regeneration	386
	11.6.	The experimental modification of CNS regeneration	387
12.		<i>Pulmonary repair and fibrosis</i>	393
		<i>A.G. Heppleston</i>	
	12.1.	Preliminary considerations	393
	12.1.1.	Morphological and physiological aspects	393
	12.1.2.	The fibrotic state	395
	12.2.	Disorders leading to pulmonary fibrosis	396
	12.2.1.	Infections	396
	12.2.1.1.	Bacterial pneumonias	396
	12.2.1.2.	Viral infections	397
	12.2.1.3.	Tuberculosis	397
	12.2.1.4.	Fungal infections	398
	12.2.2.	Granulomata	399
	12.2.2.1.	Inhaled organic dusts	399
	12.2.2.2.	Sarcoidosis	399
	12.2.2.3.	Beryllium granuloma	400
	12.2.2.4.	Eosinophilic pneumonia	401
	12.2.2.5.	Histiocytosis X	401
	12.2.2.6.	Granulomata associated with angitis	402

12.2.3.	Chronic interstitial pneumonias	402
12.2.3.1.	Usual interstitial pneumonia (IUP)	402
12.2.3.2.	Desquamative interstitial pneumonia (DIP)	403
12.2.3.3.	Lymphoid interstitial pneumonia (LIP)	406
12.2.4.	Therapeutic and toxic agents	407
12.2.4.1.	Oxygen	407
12.2.4.2.	Drugs	407
12.2.4.3.	Paraquat	409
12.2.5.	Pulmonary oedema	409
12.2.5.1.	Pathophysiology	409
12.2.5.2.	Permeability oedema	410
12.2.5.3.	Haemodynamic oedema	410
12.2.6.	Genetic, familial or congenital	411
12.2.6.1.	Interstitial fibrosis	411
12.2.6.2.	Pneumoconiosis	411
12.2.6.3.	Cystic fibrosis	411
12.2.6.4.	Immunological deficiency states	411
12.2.6.5.	Tuberosus sclerosis	412
12.2.6.6.	Ankylosing spondylitis	412
12.2.7.	Inhaled inorganic particles	412
12.2.7.1.	Silica-rich dust	413
12.2.7.2.	Silica-poor dust	414
12.2.7.3.	Complicated pneumoconiosis	416
12.2.7.4.	Fibrous silicates	417
12.2.7.5.	Immunological involvement; rheumatoid pneumoconiosis	419
12.2.7.6.	Metallic dusts	421
12.2.7.7.	Radiations	421
12.3.	Mechanisms of repair in the lung	422
12.3.1.	Fibrogenesis	422
12.3.1.1.	The macrophage fibrogenic factor (MFF)	422
12.3.1.2.	Inhibition of the macrophage factor	425
12.3.1.3.	Progression of pulmonary fibrosis	426
12.3.1.4.	Degradation of collagen	428
12.3.1.5.	Control of fibrogenesis	429
12.3.1.6.	Pharmacological aspects of pulmonary fibrosis	431
12.3.2.	Epithelial regeneration in the lung	431
12.3.2.1.	Following acute damage	431
12.3.2.2.	Following fibrosis	432
12.3.2.3.	Control mechanisms	434
12.4.	Consequences of pulmonary fibrosis	435
12.4.1.	Bronchiectasis and fibrocystic disease (honeycomb lung)	435
12.4.2.	Emphysema	435
12.4.3.	Pulmonary hypertension	436
12.4.4.	Neoplasia	437
12.4.4.1.	Scar cancer	437
12.4.4.2.	Diffuse interstitial fibrosis	437
12.4.4.3.	Pneumoconiosis	437
13.	<i>Fibrosis in the heart</i>	457
	<i>E.F. McKeown</i>	
13.1.	Introduction	457
13.2.	Pericardial fibrosis	458
13.2.1.	Pericardial adhesions	458
13.2.2.	Adhesive mediastinopericarditis (accretio cordis)	458
13.2.3.	Constrictive pericarditis	458
13.2.3.1.	Aetiology	459
13.2.3.2.	Pathological findings	459
13.3.	Myocardial fibrosis	466

13.3.1.	Ischaemic fibrosis	469
13.3.1.1.	The healing of infarcts	477
13.3.1.2.	Cardiac aneurysm	478
13.3.2.	Other causes of coronary vascular disease	479
13.3.3.	Cardiomyopathy and myocardial fibrosis	481
13.3.3.1.	Congestive cardiomyopathy	481
13.3.3.2.	Skeletal myopathy and Friedreich's ataxia	483
13.3.3.3.	Hypertrophic obstructive cardiomyopathy	485
13.3.3.4.	Obliterative cardiomyopathy	487
13.4.	Acquired valvular disease of the heart	488
13.4.1.	Rheumatic mitral disease	489
13.4.1.1.	Mitral stenosis	489
13.4.1.2.	Mitral incompetence	489
13.4.1.3.	Pathogenesis of rheumatic valvular fibrosis	490
13.4.2.	Rheumatic aortic valvulitis	493
13.4.3.	Calcific aortic stenosis	493
13.4.4.	Tricuspid rheumatic valvulitis	496
13.4.5.	Nonrheumatic aortic incompetence	496
13.4.6.	Myxomatous degeneration of cardiac valves (floppy valve syndrome)	499
13.4.7.	Jet lesions	503
13.4.8.	Friction lesions	503
13.4.9.	The carcinoid syndrome	507
13.4.9.1.	Pathological findings	508
13.4.9.2.	Pathogenesis	508
13.5.	Summary	510
14.	<i>Regeneration and repair in the kidney</i>	515
	<i>D.J. Davies and G.B. Ryan</i>	
14.1.	Introduction	515
14.2.	Methods of pathological examination of the kidney	516
14.3.	Common patterns of regeneration and scarring	517
14.3.1.	Diffuse fine scarring with no regenerative nodules	517
14.3.2.	Diffuse fine scarring with diffuse fine nodular regeneration	518
14.3.3.	Irregular coarse scarring and irregular coarse nodular regeneration	520
14.4.	General mechanisms of regeneration and repair in the kidney	522
14.4.1.	Cortical tubules and interstitium	522
14.4.2.	Glomeruli	531
14.4.3.	Medullary tubules and interstitium	532
14.5.	Compensatory hypertrophy	533
14.6.	Regeneration and repair of ischaemic renal lesions	535
14.6.1.	Acute renal ischaemia	535
14.6.2.	Chronic renal ischaemia	541
14.7.	Regeneration and repair after interference with drainage of urine	543
14.7.1.	Extrarenal obstruction – hydronephrosis and obstructive nephropathy	543
14.7.2.	Intrarenal obstruction	545
14.7.3.	Vesico-uretic reflux	545
14.8.	Nephrotoxins	545
14.8.1.	Acute toxic injury	546
14.8.2.	Chronic toxic injury	546
14.8.2.1.	Analgesic nephropathy	546
14.8.2.2.	Other chronic nephrotoxic injuries	549
14.9.	Scarring after bacterial infection of the kidney – chronic pyelonephritis	551
14.9.1.	Role of bacterial infection in chronic pyelonephritis	551
14.9.2.	Nonbacterial mechanisms in chronic pyelonephritis	555
14.9.2.1.	Vesico-uretic reflux	555
14.9.2.2.	Ischaemia	555
14.9.2.3.	Hypersensitivity reactions	556